This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Coagulation markers in patients with severe COVID-19 [COVID-19]

  • Research type

    Research Study

  • Full title

    Coagulation markers on discarded plasma samples from patients with severe COVID-19

  • IRAS ID

    283525

  • Contact name

    Deepa Arachchillage

  • Contact email

    d.arachchillage@rbht.nhs.uk

  • Sponsor organisation

    Royal Brompton and Harefield NHS Foundstion Trust

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    Patients with Corona virus Disease 19 (COVID19) seems to be at a higher risk of developing blood clots (thrombosis) mainly in their lungs which is associated with higher death. Blood clots can be in both venous and arterial circulations, clots in small blood vessels called microvascular thrombosis Coagulation abnormalities are well-known feature of severe infections but virtually in all reports, these changes and especially thrombosis, despite standard thromboprophylaxis or even with treatment dose blood thinning medications (anticoagulation) are more common in patients with COVID-19 than in other pneumonias. In addition to blood clotting protein, small cells in the blood called platelets activation seem to be important contributor in developing thrombosis in patients with COVID-19. Therefore, it is important to assess the all coagulation markers to support the further management of these patients. This is a clinical priority especially for those with bleeding with normal standard coagulation parameters and normal or hypercoagulable state shown in the assessment of coagulation state using a test called Thromboelastography. \nIn this proposed study we aim to assess the coagulation markers on discarded plasma samples (no DNA or cells) from patients with severe COVID-19 at Royal Brompton & Harefield NHS Foundation Trust (RBHT). Patients diagnosed with COVID-19 at the Trust (through positive molecular or serology tests) have routine haemostasis tests performed for clinical care and the research will use discarded samples to perform proposed tests of haemostasis which will be analysed against some clinical information from the patients’ clinical records, routine laboratory and point of care tests will be fully anonymised before analysing. There is no additional blood sampling or clinical intervention done for research purpose. All data will be stored on password protected computer at RBHT and access only allowed to clinical team directly caring for the patients.

  • REC name

    East of England - Cambridge East Research Ethics Committee

  • REC reference

    20/EE/0160

  • Date of REC Opinion

    11 Jun 2020

  • REC opinion

    Further Information Favourable Opinion